Concentriq AP
Research-use digital pathology platform with AI capabilities
Platform · Cloud SaaSCompany source
Company profile
About Proscia
Proscia accelerates pathology's transformation toward a data-driven discipline with its Concentriq digital pathology platform and AI solutions.
Company description Proscia official website
Mission. Intelligence for the Decisions that Matter Most.
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at Proscia?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ADC therapies
- Breast Cancer
- Colorectal cancer
- Immune checkpoint inhibitor therapies
- Lung cancer
- Ovarian cancer
- Prostate cancer
- Skin cancer
Who it serves
- Academic Medical Centers
- Clinical Labs
- CROs
- Health Systems
- Pharmaceutical Companies
- Reference Labs
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: 230+ AI apps from Ibex, Mindpeak, Visiopharm, Aiforia, Waiv, 45+ scanner types including Hamamatsu NanoZoomer S360MD, Epic Beaker, Most LIS systems (bidirectional sync).
Geographic context
MarketsCanada · Europe · Global (4,000+ hospitals and clinics worldwide) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launched Fifth Generation of Concentriq with AI-native architecture, achieved Best in KLAS 2026 rating (highest-rated in both US and Europe), 100% customer repurchase intent in KLAS survey
Partnerships
Recorded partners
- Aiforia
- Global lab network via Proscia Aperture
- Hamamatsu
- Ibex
- IQVIA Laboratories
- Mindpeak
- Visiopharm
- Waiv
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Concentriq AP-Dx
FDA-cleared digital pathology platform for primary clinical diagnosis
Platform · Cloud SaaSCompany source
Concentriq LS
Pathology AI platform for life sciences and drug development
Platform · Cloud SaaSCompany source
Proscia Aperture
Real-world multimodal pathology data network for research
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Corrigendum to 'Intrapartum electronic fetal heart rate monitoring to predict acidemia at birth with the use of deep learning' [American Journal of Obstetrics and Gynecology 232/1 (2025) 116-117].American journal of obstetrics and gynecology · Sep 1, 2026
Report on the 2025 DICOM WSI Connectathon.Journal of pathology informatics · Apr 1, 2026
Inhibition of Muscle-Specific Protein Kinase (MuSK) Releases Organophosphate-Aged Acetylcholinesterase (AChE) from C2C12 Cells.Toxics · Sep 29, 2025
A randomised control trial to compare conventional and haemostatic dressings in radial arterial access: Assessment of Radial Artery Complications Whilst Achieving Rapid Haemostasis (ARCH Trial).International journal of cardiology · Feb 1, 2025
Intrapartum electronic fetal heart rate monitoring to predict acidemia at birth with the use of deep learning.American journal of obstetrics and gynecology · Jan 1, 2025
Evaluating equity in performance of an electronic health record-based 6-month mortality risk model to trigger palliative care consultation: a retrospective model validation analysis.BMJ quality & safety · Sep 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
81% pathologist preference over microscope
HNL Lab Medicine
68% faster same-day case turnaround
P&C Labs
>$1M new revenue from existing case volume
PathGroup
~51% storage cost reduction
Automatic tiering based on lab usage modeling
100% customer repurchase intent
KLAS 2026 survey
2x higher likelihood of approval
Biomarker-driven trials
Cleveland Clinic
Digital pathology platform adoption maintaining pathologist workflow
Proscia replicated muscle memory pathologists built over decades at the microscope
HNL Lab Medicine
Digital pathology adoption for clinical case review
81% of pathologists prefer Concentriq to the microscope
IQVIA Laboratories
Standardization of clinical trial operations and patient enrollment
Standardization aids in patient enrollment, stratification, randomization and endpoint evaluation in clinical trials
P&C Labs
Accelerating same-day case turnaround time
68% faster same-day case turnaround
PathGroup
Revenue generation from existing case volume through digital pathology
>$1M new revenue from existing case volume
Quest Diagnostics
Integration of AI image analysis applications in clinical workflow
230+ AI apps from partners integrated into workflow
South Bend Medical Foundation
Digital pathology transformation
Successful digital pathology deployment
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Proscia
Recent articles published on Proscia's official website.
The Next Chapter in Proscia’s Mission
Read on ProsciaHow Unilabs is Advancing Digital Pathology and Precision Medicine with Proscia
Read on ProsciaFreedom to Grow: Why an Open, Interoperable Platform Is Non-Negotiable for Digital Pathology
Read on ProsciaPut your proprietary AI to work across R&D
Read on ProsciaGetting to Know Kary Rogers: A Conversation with Proscia’s Head of Support
Read on Proscia07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
Digital Pathology Alliance Aims to Streamline AI-Powered Cancer Diagnostic Development
Imagene AI's integration with Proscia's platform creates end-to-end pathway for pharmaceutical companies to develop companion diagnostics from discovery through clinical deployment.
Drug Discovery & Research · Aug 20, 2026
FDA Grants Proscia Regulatory Fast Lane to Solve Digital Pathology's Interoperability Crisis
New clearance with Predetermined Change Control Plan allows platform to add scanner compatibility without repeated FDA submissions, addressing a major barrier to digital pathology adoption.
Policy & Regulation · Aug 14, 2026
AI Pathology Tool Catches Diagnostic Errors in 5% of Prostate Biopsies in Major NHS Trial
Real-world study across three UK health trusts shows Tempus's AI software reduced turnaround times by nearly a day while prompting clinically significant diagnostic changes in over 1% of cases.
Clinical AI · Jul 17, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.